ETOR vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 30, 2026

ETOR

36.8
AI Score
VS
HIVE Wins

HIVE

39.5
AI Score

Investment Advisor Scores

ETOR

37score
Recommendation
AVOID NEW MONEY

HIVE

40score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric ETOR HIVE Winner
Forward P/E 7.6805 62.8931 ETOR
PEG Ratio 0 0 Tie
Revenue Growth -24.6% 73.5% HIVE
Earnings Growth 87.1% -99.9% ETOR
Tradestie Score 36.8/100 39.5/100 HIVE
Profit Margin 2.2% -98.5% ETOR
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

ETOR 1M: -19.0% · 3M: -36.3% HIVE 1M: +10.6% · 3M: -9.9%

Current Technical Phase

ETOR

Markdown
Sell / avoid

Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 29

RSI (14): 29.2 · Price: $25.78

HIVE

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -3.2%) with fading momentum, RSI 44

RSI (14): 44.2 · Price: $2.92

Fundamentals Snapshot

Metric ETOR HIVE
Market Cap — —
Forward P/E 8.5 -5.7
Trailing P/E 9.2 —
Revenue (TTM) — —
Revenue Growth -0.2% 0.7%
Gross Margin 0.0% 0.4%
Operating Margin 0.0% -0.6%
EPS 2.78 -1.39
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.